{"id":"NCT00547521","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase IIIB Subcutaneous Abatacept Monotherapy Study","officialTitle":"A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-12","completion":"2014-02","firstPosted":"2007-10-22","resultsPosted":"2011-01-24","lastUpdate":"2015-03-23"},"enrollment":119,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis (RA)"],"interventions":[{"type":"DRUG","name":"abatacept","otherNames":["BMS-188667","OrenciaÂ®"]},{"type":"DRUG","name":"Methotrexate (MTX)","otherNames":[]}],"arms":[{"label":"Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort","type":"EXPERIMENTAL"},{"label":"SC Abatacept Monotherapy Cohort","type":"EXPERIMENTAL"}],"summary":"To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept","primaryOutcome":{"measure":"Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study","timeFrame":"Day 113","effectByArm":[{"arm":"Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort","deltaMin":0,"sd":null},{"arm":"SC Abatacept Monotherapy Cohort","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":22,"countries":["United States","Australia","Mexico","South Africa"]},"refs":{"pmids":["23097311"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":51},"commonTop":["Upper respiratory tract infection","Sinusitis","Urinary tract infection","Headache","Bronchitis"]}}